Matthew John Paul

Matthew John Paul

Auto-generated profile, based on publicly available information

Matthew John Paul

Institute for Infection and Immunity, St. George's University of London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2015 in Plant Biotechnology Journal
Verified
Journal Article
Open access
PDF file
JMJulian K‐C. Ma
Julian K‐C. Ma
JDJürgen Drossard
Jürgen Drossard
DLDavid Lewis
David Lewis
FAFriedrich Altmann
Friedrich Altmann
JBJulia Boyle
Julia Boyle
RFRainer Fischer
Rainer Fischer
Summary: Although plant biotechnology has been widely investigated for the production of clinical‐grade monoclonal antibodies, no antibody products derived from transgenic plants have yet been approved by pharmaceutical regulators for clinical testing. In the Pharma‐Planta project, the HIV‐neutralizing human monoclonal antibody 2G12 was expressed in transgenic tobacco (Nicotiana tabacum). The scientific, technical and regulatory demands of good manufacturing practice (GMP) were addressed by comprehensive molecular characterization of the transgene locus, confirmation of genetic and phenotypic stability over several generations of transgenic plants, and by establishing standard operating procedures for the creation of a master seed bank, plant cultivation, harvest, initial processing, downstream processing and purification. The project developed specifications for the plant‐derived antibody (P2G12) as an active pharmaceutical ingredient (API) based on (i) the guidelines for the manufacture of monoclonal antibodies in cell culture systems; (ii) the draft European Medicines Agency Points to Consider document on quality requirements for APIs produced in transgenic plants; and (iii) de novo guidelines developed with European national regulators. From the resulting process, a GMP manufacturing authorization was issued by the competent authority in Germany for transgenic plant‐derived monoclonal antibodies for use in a phase I clinical evaluation. Following preclinical evaluation and ethical approval, a clinical trial application was accepted by the UK national pharmaceutical regulator. A first‐in‐human, double‐blind, placebo‐controlled, randomized, dose‐escalation phase I safety study of a single vaginal administration of P2G12 was carried out in healthy female subjects. The successful completion of the clinical trial marks a significant milestone in the commercial development of plant‐derived pharmaceutical proteins.

1 January 2011 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
MPMatthew Paul
Matthew Paul
JMJulian K‐C. Ma
Julian K‐C. Ma

26 May 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
PDPascal M. W. Drake
Pascal M. W. Drake
TBTommaso Barbi
Tommaso Barbi
ASAmy Sexton
Amy Sexton
EMEdward McGowan
Edward McGowan
JSJohannes Stadlmann
Johannes Stadlmann
JMJulian K.-C. Ma
Julian K.-C. Ma
Rhizosecretion is an attractive technology for the production of recombinant proteins from transgenic plants. However, to date, yields of plantderived recombinant pharmaceuticals by this method have been too low for commercial viability. Studies conducted focused on three transgenic plant lines grown in hydroponic culture medium, two expressing monoclonal antibodies Guy's 13 and 4E10 and one expressing a small microbicide polypeptide cyanovirin‐N. Rhizosecretion rates increased significantly by the addition of the plant growth regulator α‐naphthalene acetic acid. The maximum rhizosecretion rates achieved were 58 Hg/g root dry weight/24 h for Guy's 13, 10.43 μg/g root dry weight/24 h for 4E10, and 766 μg/g root dry weight/24 h for cyanovirin‐N, the highest figures so far reported for a full‐length antibody and a recombinant protein, respectively. The plant growth regulators indolebutyric acid, 6–benzylaminopurine, and kinetin were also demonstrated to increase rhizosecretion of Guy's 13. The effect of the growth regulators differed, as α‐naphthalene acetic acid and indole‐butyric acid increased the root dry weight of hydroponic plants, whereas the cytokinins benzylaminopurine and kinetin increased rhizosecretion without affecting root mass. A comparative glycosylation analysis between MAb Guy's 13 purified from either hydroponic culture medium or from leaf extracts demonstrated a similar pattern of glycosylation comprising high mannose to complex glycoforms. Analysis of the hydroponic culture medium at harvest revealed significantly lower and less complex levels of proteolytic enzymes, in comparison with leaf extracts, which translated to a higher proportion of intact Guy's 13 IgG in relation to other IgG products. Hydroponic medium could be added directly to a chromatography column for affinity purification, allowing simple and rapid production of high purity Guy's 13 antibody. In addition to the attractiveness of controlled cultivation within a contained environment for pharmaceutical‐producing plants, this study demonstrates advantages with respect to the quality and downstream purification of recombinant proteins.—Drake, P. M. W., Barbi, T., Sexton, A., McGowan, E., Stadlmann, J., Navarre, C., Paul, M. J., Ma, J. K.‐C. Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco. FASEB J . 23, 3581–3589 (2009). www.fasebj.org

2 December 2019 in Expert Review of Vaccines
Verified
Journal Article
Open access
ESElena Stylianou
Elena Stylianou
MPMatthew J. Paul
Matthew J. Paul
RRRajko Reljic
Rajko Reljic
HMHelen McShane
Helen McShane
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could be achieved. The route of entry of Mycobacterium tuberculosis, the causative organism, is via inhalation making TB primarily a respiratory disease. There is therefore good reason to hypothesize that a mucosally delivered vaccine against TB could be more effective than one delivered via the systemic route.Areas covered: This review summarizes the progress that has been made in the area of TB mucosal vaccines in the last few years. It highlights some of the strengths and shortcomings of the published evidence and aims to discuss immunological and practical considerations in the development of mucosal vaccines.Expert opinion: There is a growing body of evidence that the mucosal approach to vaccination against TB is feasible and should be pursued. However, further key studies are necessary to both improve our understanding of the protective immune mechanisms operating in the mucosa and the technical aspects of aerosolized delivery, before such a vaccine could become a feasible, deployable strategy.

30 December 2011 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
VHVerena K Hehle
Verena K Hehle
MPMatthew J Paul
Matthew J Paul
PDPascal M Drake
Pascal M Drake
JMJulian Kc Ma
Julian Kc Ma
CDCraig J van Dolleweerd
Craig J van Dolleweerd
Background: Interest in using plants for production of recombinant proteins such as monoclonal antibodies is growing, but proteolytic degradation, leading to a loss of functionality and complications in downstream purification, is still a serious problem.Results: In this study, we investigated the dynamics of the assembly and breakdown of a human IgG1κ antibody expressed in plants. Initial studies in a human IgG transgenic plant line suggested that IgG fragments were present prior to extraction. Indeed, when the proteolytic activity of non-transgenicNicotiana tabacumleaf extracts was tested against a human IgG1 substrate, little activity was detectable in extraction buffers with pH > 5. Significant degradation was only observed when the plant extract was buffered below pH 5, but this proteolysis could be abrogated by addition of protease inhibitors. Pulse-chase analysis of IgG MAb transgenic plants also demonstrated that IgG assembly intermediates are present intracellularly and are not secreted, and indicates that the majority of proteolytic degradation occurs following secretion into the apoplastic space.Conclusions: The results provide evidence that proteolytic fragments derived from antibodies of the IgG subtype expressed in tobacco plants do not accumulate within the cell, and are instead likely to occur in the apoplastic space. Furthermore, any proteolytic activity due to the release of proteases from subcellular compartments during tissue disruption and extraction is not a major consideration under most commonly used extraction conditions.

1 August 2013 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
MPMathew J. Paul
Mathew J. Paul
ATAudrey Teh
Audrey Teh
RTRichard Twyman
Richard Twyman
JMJulian K-C. Ma
Julian K-C. Ma
Four major developments have taken place in the world of Molecular Pharming recently. In the USA, the DARPA initiative challenged plant biotechnology companies to develop strategies for the large-scale manufacture of influenza vaccines, resulting in a successful Phase I clinical trial; in Europe the Pharma-Planta academic consortium gained regulatory approval for a plant-derived monoclonal antibody and completed a first-in-human phase I clinical trial; the Dutch pharmaceutical company Synthon acquired the assets of Biolex Therapeutics, an established Molecular Pharming company with several clinical candidates produced in their proprietary LEX system based on aquatic plants; and finally, the Israeli biotechnology company Protalix Biotherapeutics won FDA approval for the commercial release of a recombinant form of the enzyme glucocerebrosidase produced in carrot cells, the first plant biotechnology-derived biopharmaceutical in the world approved for the market. Commercial momentum is gathering pace with additional candidates now undergoing or awaiting approval for phase III clinical trials. Filling the product pipeline is vital to establish commercial sustainability, and the selection of appropriate target products for Molecular Pharming will be a critical factor. An interesting feature of the four stories outlined above is that they span the use of very different platform technologies addressing different types of molecules which aim to satisfy distinct market demands. In each case, Molecular Pharming was an economically and technically suitable approach, but this decisionmaking process is not necessarily straightforward. Although the various technologies available to Molecular Pharming are broad ranging and flexible, competing technologies are better established, so there needs to be a compelling reason to move into plants. It is most unlikely that plant biotechnology will be the answer for the whole biologics field. In this article, we discuss the current plant biotechnology approaches that appear to hold the greatest promise and in doing so attempt to define the product areas that are most likely to benefit from different Molecular Pharming technologies.